Review
doi: 10.1586/14737140.7.5.735.
Novel small-molecule therapy of Hodgkin lymphoma
Affiliations
- PMID: 17492936
- DOI: 10.1586/14737140.7.5.735
Item in Clipboard
Review
Novel small-molecule therapy of Hodgkin lymphoma
Expert Rev Anticancer Ther.
2007 May.
Abstract
The treatment of Hodgkin lymphoma continues to be based on combination chemotherapy and radiation therapy. Although this treatment strategy produces a high cure rate, short- and long-term toxic effects continue to be problematic for young cured patients. In this review we focus on emerging novel therapies using small molecules that target specific survival pathways in the cancer cells. This approach is aimed at improving the cure rate while reducing treatment-related toxicity.
Similar articles
-
Radiation and new molecular agents, part II: targeting HDAC, HSP90, IGF-1R, PI3K, and Ras.Semin Radiat Oncol. 2006 Jan;16(1):59-64. doi: 10.1016/j.semradonc.2005.08.008. Semin Radiat Oncol. 2006. PMID: 16378908 Review.
-
The role of small molecule inhibitors for veterinary patients.Vet Clin North Am Small Anim Pract. 2007 Nov;37(6):1121-36; vii. doi: 10.1016/j.cvsm.2007.06.003. Vet Clin North Am Small Anim Pract. 2007. PMID: 17950886 Review.
-
MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.Leuk Res. 2008 Sep;32(9):1382-92. doi: 10.1016/j.leukres.2008.02.018. Epub 2008 Apr 3. Leuk Res. 2008. PMID: 18394702
-
Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.Oncologist. 2009 May;14(5):511-25. doi: 10.1634/theoncologist.2008-0214. Epub 2009 May 1. Oncologist. 2009. PMID: 19411316 Review.
-
Molecularly targeted therapy for melanoma: current reality and future options.Cancer. 2006 Nov 15;107(10):2317-27. doi: 10.1002/cncr.22273. Cancer. 2006. PMID: 17039502 Review.
Cited by
-
Lestaurtinib inhibition of the Jak/STAT signaling pathway in hodgkin lymphoma inhibits proliferation and induces apoptosis.PLoS One. 2011 Apr 20;6(4):e18856. doi: 10.1371/journal.pone.0018856. PLoS One. 2011. PMID: 21533094 Free PMC article.
-
Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma.Blood Rev. 2010 Nov;24(6):233-8. doi: 10.1016/j.blre.2010.08.003. Epub 2010 Sep 15. Blood Rev. 2010. PMID: 20828898 Free PMC article. Review.
-
Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review.J Immunol Res. 2015;2015:968212. doi: 10.1155/2015/968212. Epub 2015 Dec 16. J Immunol Res. 2015. PMID: 26788526 Free PMC article. Review.
-
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma.Eur J Nucl Med Mol Imaging. 2014 May;41(5):867-77. doi: 10.1007/s00259-013-2658-6. Epub 2014 Jan 17. Eur J Nucl Med Mol Imaging. 2014. PMID: 24435772 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
